Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Other Non-Current Liabilities (2021 - 2025)

Foghorn Therapeutics has reported Other Non-Current Liabilities over the past 3 years, most recently at $556000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $556000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $556000.0 (changed N/A YoY), and the annual figure for FY2025 was $556000.0, changed.
  • Other Non-Current Liabilities for Q4 2025 was $556000.0 at Foghorn Therapeutics, down from $656000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for FHTX hit a ceiling of $856000.0 in Q1 2025 and a floor of $29000.0 in Q4 2022.
  • Median Other Non-Current Liabilities over the past 3 years was $157000.0 (2021), compared with a mean of $343000.0.
  • Peak annual rise in Other Non-Current Liabilities hit 66.08% in 2022, while the deepest fall reached 79.72% in 2022.
  • Foghorn Therapeutics' Other Non-Current Liabilities stood at $143000.0 in 2021, then tumbled by 79.72% to $29000.0 in 2022, then surged by 1817.24% to $556000.0 in 2025.
  • The last three reported values for Other Non-Current Liabilities were $556000.0 (Q4 2025), $656000.0 (Q3 2025), and $757000.0 (Q2 2025) per Business Quant data.